Drugs / Imdusiran
Imdusiran
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06154278 | Jul 2024 → Dec 2026 expected | chronic hepatitis B virus infection | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 2 | NCT06245291 | May → Aug 2024 | chronic hepatitis B virus infection | Arbutus Biopharma Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT04980482 | Oct 2021 → Mar 2025 | chronic hepatitis B virus infection | Arbutus Biopharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT04820686 | May 2021 → Mar 2023 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04847440 | Mar 2021 → Sep 2022 | chronic hepatitis B virus infection, hepatitis D virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imdusiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154278 ↗ |
| Known as | AB-729 | “Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection” NCT06245291 ↗ |
| Known as | AB-729 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314644 ↗ |
| Action | Inhibit | “AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV.” NCT04820686 ↗ |
| Modality | Small interfering RNA (siRNA) | “AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV.” NCT04820686 ↗ |
| Route | Subcutaneous | “Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.” NCT04820686 ↗ |